2024 biotech funding tracker: recent highlights

January 2024: 

• Advesya (France): €23 million seed | cancer therapies
• Cumulus Oncology (United Kingdom): £9 million ($11.45 million) seed | cancer drug discovery
• DISCO Pharmaceuticals (Germany): EUR 20 million ($21.75 million) seed | drug discovery | map of small cell lung cancer surfaceome completed

February 2024: 

• Alys Pharmaceuticals (United States): $100M seed | immuno-dermatology | clinical in skin diseases
• Bioptimus (France): $35 million seed | AI-enabled drug discovery IsomAb (UK): £7.5 million ($9.46 million) seed | preclinical in peripheral arterial disease

March 2024:

• Relation Therapeutics (United Kingdom): $35 million seed | multi omics for drug discovery | discovery in osteoporosis

April 2024:

• Neurosterix (Switzerland): $63 million seed | allosteric modulator therapeutics | preclinical in schizophrenia
• Seamless Therapeutics (Germany) : $12.5 million seed | gene editing
• Outrun Therapeutics (United Kingdom) : $10 million seed | E3 ligase inhibitors | solid tumors

January 2024: 

• Claris Bio (United States): $57 million series A | corneal therapies | phase 1/2 clinical trial in neurotrophic keratitis
• Resalis Therapeutics (Italy): €10 million ($10.95 million) series A | non-coded RNA-based therapeutics | phase 1 in obesity
• OnCusp Therapeutics (United States): $100 million series A | oncology assets | preclinical in solid tumors
• Myrobalan Therapeutics (United States): $24 million series A | CNS disease therapies | IND-enabling in multiple sclerosis, Alzheimer’s disease, and amyotrophic lateral sclerosis
• Calluna Pharma (Norway): EUR 75 million ($81.71 million) series A | immune-related therapies | phase 1 in fibrosis
• Tr1X, Inc. (United States): $75 million series A | regulatory T cell-based therapies | phase 1 in graft versus host disease
• Granata Bio (United States): $14 million series A | women’s health | phase 3 in infertility
• AQEMIA (France): €60 million ($65.02 million) series A | AI-enabled drug discovery
• Imu Biosciences (United Kingdom): £11.5 million ($14.57 million) series A | immune discovery platform for precision medicines
• Sagimet Biosciences (United States): $112.5 million series A | phase 3 in nonalcoholic steatohepatitis
• COUR Pharmaceuticals (United States): $105 million series A | phase 2 in celiac disease
• Synnovation Therapeutics (United States): $102 million series A | small molecule therapies | clinical in solid tumors
• ZWI Therapeutics, Inc. (United States): $10 million series A | protein therapeutics | preclinical in refractory gout
• Moonwalk Biosciences (United States): $57 million series A | precision epigenetic medicines

February 2024: 

• Anbogen (Taiwan): $12.5 million series A | precision oncology | phase 2 in non-small cell lung cancer
• Basking Biosciences (United States): $55 million series A | acute thrombolytic therapy | phase 2 in acute ischemic stroke
• Latigo Biotherapeutics (USA): $135 million series A | non-opioid pain medicines | phase 1 in acute and chronic pain
• Firefly Bio (USA): $94 million series A | degrader antibody conjugates | preclinical in solid and liquid tumors
• Curve Therapeutics (UK): £40.5 million Series A | Small molecule drug discovery | Discovery stage in solid tumors
• Baseimmune (UK): $11.3 million in Series A | AI-enabled vaccine platform | Preclinical in coronavirus

March 2024:

• Kenai Therapeutics (USA): $82 million series A | stem cell therapy | preclinical in moderate to severe Parkinson’s disease.
• Tierra Biosciences (United States): $11.4 million series A | AI-derived protein synthesis
• Asgard Therapeutics (Sweden) | €30 million ($32.53 million) series A | cancer immunotherapies | preclinical in cancer
• Mirador Therapeutics (United States) | $400 million series A | precision medicines
• Clasp Therapeutics (United States) | $150 million series A | T cell engagers
• Avenzo Therapeutics (United States) | $150 Million series A | cancer drugs | clinical in HR+ breast cancer
• Edgewood Oncology (United States) | $20 million series A | cancer drugs | phase 1 in acute myeloid leukemia

April 2024:

• Rhythm Pharmaceuticals (United States): $150 million series A | (MC4R) pathway-related treatments | phase 3 in obesity
• Diagonal Therapeutics (United States) : $128 million series A | antibody discovery | preclinical in hereditary hemorrhagic telangiectasia
• Seaport Therapeutics (United States) : $100 million series A | antidepressants and anxiolytics | phase 1 in major depression with anxiety
• DeepCure (United States) : $24.6 million series A-1 | small molecules | discovery in inflammatory and immunological conditions
• Corner Therapeutics (United States) : $54 million series A | cancer vaccines
• Rubedo Life Sciences (United States) : $40 million series A | chronic disease therapies | IND-enabling in chronic atopic dermatitis and chronic psoriasis
• Flindr Therapeutics (Netherlands) : €20 million ($21.38 million) series A | precision oncology | preclinical in ovarian cancer
• Brise Pharmaceuticals (China) : $20 million in pre-series A and series A | pain management | phase 1 in chronic low back pain

January 2024: 

• Vico Therapeutics (Netherlands): $60 million (€54 million) series B | RNA modulation | phase 1/2 in spinocerebellar ataxia type 3
• Full-Life Technologies (China, Belgium): $47.3 million series B | radionuclide drug conjugates | first-in-human trial in prostate cancer
• Avistone Biotechnology (China): 1 billion Chinese yuan (~$140 million) series B | targeted cancer drugs | clinical in non-small cell lung cancer
• HI-Bio (United States): $95 million series B | precision medicine | phase 2 in primary membranous nephropathy
• Stalicla (Switzerland): $17.4 million series B | neurodevelopmental disorder-specific precision medicine platform | phase 1b in autism spectrum disorder
• Cyrano Therapeutics (United States): $9 million series B | phase 2 in post-viral smell loss
• Ratio Therapeutics (United States): $50 million series B | radiotherapies | phase 1 in epithelial-derived cancers
• Comanche Biopharma (United States): $75 million series B | siRNA therapy | phase 1 in preeclampsia
• Enterprise Therapeutics (United Kingdom): £26 million ($33.1 million) series B | respiratory diseases therapies | phase 2a in cystic fibrosis

February 2024: 

• NeoPhore (United Kingdom): £9.6 million ($12.2 million) series B | immuno‑oncology therapies | drug discovery in solid tumors
• Attralus (United States): $56 million series B | pan-amyloid removal therapeutics | phase 1 in systemic amyloidosis
• ProfoundBio (United States): $112 million series B | antibody drug conjugates | phase 2 in solid tumors

March 2024:

• BlossomHill Therapeutics (USA): $100 million series B | small molecule medicines | preclinical in oncology.
• Nocion Therapeutics (USA): $62 million series B | small molecule medicines | phase 2b in chronic cough.
• Engrail Therapeutics (United States) | $157 million series B | precision neuroscience | phase 2 in generalized anxiety disorder
• Tubulis (Germany) | €128 million ($138.75 million) series B2 | antibody drug conjugates | preclinical in multiple solid tumors
• Capstan Therapeutics (United States) | $175 million series B | RNA-based therapies | preclinical in autoimmune disorders

April 2024:

• Alterome Therapeutics (United States) : $132 million series B | small molecules | IND-enabling studies in breast and endometrial cancers
• TORL BioTherapeutics (United States) : $158 million series B-2 | antibody drug conjugates | early-stage clinical in CLDN 6+ tumors
• SynOx Therapeutics (Ireland, United Kingdom) : $75 million series B | monoclonal antibodies | phase 3 in tenosynovial giant cell tumor
• Pathios Therapeutics (United Kingdom) : $25 million series B | cancer therapies | preclinical in solid tumors

January 2024:

• Accent Therapeutics (United States): $75 million series C | small molecule therapies | IND-enabling in breast, ovarian, colorectal, and endometrial cancers
• PRISM BioLab (Japan): 1.5 billion yen ($10.3 million) series C | drug discovery platform | phase 2 in cancer

February 2024: 

• Halia Therapeutics (United States): $30 million series C | anti-inflammatory therapeutics | phase 2 in myelodysplastic syndromes
• Frontier Medicines (USA): $80 million Series C | Precision medicine | Phase 1 in KRAS mutant cancers

March 2024:

• Alumis (United States): $259 million series C | precision immunology | phase 2 in psoriasis
• Sionna Therapeutics (United States): $182 million series C | small molecule therapies | phase 1 in cystic fibrosis
• Siolta Therapeutics (United States): $12 million series C | live biotherapeutics | phase 2 in atopic dermatitis, food allergy and allergic asthma

April 2024:

• Obsidian Therapeutics (United States) : $160.5 million series C | TIL therapy | phase 1 in melanoma
• Asher Bio (United States) : $55 million series C | immunotherapies | phase 1 in solid tumors

February 2024: 

• BioAge (United States): $170 million series D | metabolic disease drug discovery platform | phase 2 in obesity

February 2024: 

• Neurona Therapeutics (United States): $120 million series E | cell therapies | phase 1/2 in focal epilepsies

March 2024:

• FogPharma (USA): $145 million series E | precision medicine | phase 1/2 in advanced or metastatic solid tumors.

January 2024: 

• Immunic Therapeutics (United States): $240 million PIPE | small molecules | phase 3 in relapsing multiple sclerosis
• ORIC Pharmaceuticals (United States): $125 million PIPE | cancer treatments | phase 1b in multiple myeloma
• Kura Oncology (United States): $150 million PIPE | precision medicine | registration-directed trial in acute myeloid leukemia

February 2024: 

• Adverum Biotechnologies (United States): $127.5 million PIPE | gene therapy | phase 2 in wet age-related macular degeneration
• Silence Therapeutics (United Kingdom): $120 million PIPE | precision medicine | phase 2 in cardiovascular disease
• BioSenic (Belgium): €500,000 ($538,000) PIPE | regenerative and immune medicine | phase 2b in chronic graft vs host disease
• Mineralys Therapeutics (United States): $120 million PIPE | aldosterone synthase inhibitor | phase 2 in hypertension
• Cogent Biosciences (USA): $225 million PIPE | precision medicine | phase 3 in gastrointestinal stromal tumors
• Denali Therapeutics (USA): $500 million PIPE | Neurodegenerative disease therapeutics | Clinical in Hunter syndrome

March 2024:

• Applied Therapeutics (USA): $100 million PIPE | aldose reductase inhibitors | phase 3 in galactosemia.
• Regulus Therapeutics (United States): $100 million PIPE | RNA-based therapies | phase 1 in polycystic kidney disease
• Lexeo Therapeutics (United States): $95 million PIPE | genetic medicines | phase 1/2 in cardiac Friedreich’s ataxia
• Spyre Therapeutics (United States): $180 million PIPE | monoclonal antibodies | preclinical in inflammatory bowel disease
• Cybin (Canada): $150 million PIPE | mental healthcare | phase 2 in major depressive disorder
• Unicycive (United States): $50 million PIPE | kidney disease treatments | phase 1 in hyperphosphatemia
• Elicio Therapeutics (United States): $6 million PIPE | immunotherapies | phase 2 in pancreatic ductal adenocarcinoma

April 2024:

• Avalo (United States): $115.6 million PIPE | targeted therapies | phase 1 in hidradenitis suppurativa
• CervoMed (United States): $50 million PIPE | neurodegenerative disease therapies | phase 2b ion dementia
• Surrozen (United States): $17.5 million PIPE | targeted antibodies | phase 1 in severe alcoholic hepatitis
• Acrivon Therapeutics (United States) : $130 million PIPE | precision proteomics | phase 2 in ovarian, endometrial, and bladder cancers
• Protara Therapeutics (United States) : $45 million PIPE | cancer and rare disease therapies | phase 2 in non-muscle invasive bladder cancer
• Cullinan Therapeutics (United States) : $280 million PIPE | modality-agnostic targeted therapies | phase 3 in non-small cell lung cancer
• Eliem Therapeutics (United States, United Kingdom) : $120 million PIPE | nervous system disorder treatments | phase 1 in major depressive disorder
• Century Therapeutics (United States) : $60 million PIPE | stem cell therapies | phase 1 in blood cancers
• Leap Therapeutics (United States) : $40 million PIPE | cancer immunotherapies | phase 2 in gastric cancer
• Zura Bio (United States) : $112.5 million PIPE | immunotherapies | phase 2 in autoimmune and inflammatory diseases
• Korro Bio (United States) : $70 million PIPE | RNA editing | phase 1/2 in alpha-1 antitrypsin deficiency
• Benitec Biopharma (United States) : $40 million PIPE | gene therapies | phase 1b/2a in oculopharyngeal muscular dystrophy

January 2024:

• Dyne Therapeutics (United States): $300 million public offering | oligonucleotide therapeutics | phase 1/2 in myotonic dystrophy type 1
• Kymera Therapeutics (United States): $275 million public offering | targeted protein degradation | phase 2 in hidradenitis suppurativa and atopic dermatitis
• Praxis Precision Medicines (United States): $150 million public offering | precision medicine | clinical in pediatric patients with early-onset SCN2A developmental and epileptic encephalopathy
• Dyne Therapeutics (United States): $345.1 million public offering | muscle disease therapies | clinical in myotonic dystrophy type 1
• XORTX (Canada): $2 million public offering | orphan disease indications | phase 2 in polycystic kidney disease
• Immatics (Germany): $175 million public offering | phase 1 in recurrent and refractory solid tumors
• Viridian Therapeutics (United States): $150 million public offering | antibody discovery and engineering | phase 3 in thyroid eye disease
• TransCode Therapeutics (United States): $7.25 million public offering | clinical in metastatic cancer
• Vaxcyte (United States): $750 million public offering | pneumococcal conjugate vaccines | phase 2 in pneumococcal disease
• CG Oncology (United States): $380 million IPO | targeted oncolytic immunotherapy | phase 3 in bladder cancer
• ArriVent Biopharma (United States): $175 million IPO | cancer therapeutics | phase 3 in non-small cell lung cancer
• Tourmaline Bio (United States): $172.5 million public offering | immune and inflammatory disease therapies | phase 2 in thyroid eye disease
• Panbela Therapeutics (United States): $9 million public offering | cancer therapies | phase 3 in pancreatic cancer

February 2024: 

• Vaxcyte (United States): $862.5 million public offering | vaccine technology | phase 2 in pneumococcal disease
• Vera Therapeutics (United States): $250 million public offering | immunologic disease therapeutics | phase 3 in IgA nephropathy
• Alto Neuroscience (United States): $128.6 million IPO | precision medicine | phase 2b in major depressive disorder
• Fractyl Health (United States): $110.0 million IPO | metabolic therapeutics | preclinical in obesity
• Corbus Pharmaceuticals (United States): $94.5 million public offering | precision oncology | IND clearance in solid tumors |
• Immix Biopharma (United States): $15 million public offering | cell therapy | phase 1b/2a in relapsed/refractory amyloidosis and relapsed/refractory multiple myeloma
• Kyverna Therapeutics (United States): $319 million IPO | cell engineering | phase 2 in B-cell driven autoimmune diseases
• Metagenomi (United States): $93.75 million IPO | precision genetic medicines | preclinical in hemophilia A
• PepGen (United States): $80.1 million public offering | gene therapies | phase 2 in Duchenne muscular dystrophy
• Tenax Therapeutics (United States): $9 million public offering | precision medicine | phase 3 in acute decompensated heart failure
• Larimar Therapeutics (USA): $150 million public offering | rare disease therapeutics | phase 1 in Friedreich’s ataxia
• Iovance Biotherapeutics (USA): $211 million underwritten offering | phase 3 in melanoma

March 2024: 

• Viking Therapeutics (USA): $550 million public offering | metabolic and endocrine disorder therapies | phase 2b in nonalcoholic steatohepatitis.
• BioVie (USA): $21 million public offering | liver and neurodegenerative disease therapeutics | phase 3 in Alzheimer’s disease.
• Apogee Therapeutics (United States): $420 million public offering | biologics | phase 1 in atopic dermatitis
• Eupraxia Pharmaceuticals (Canada): C$30 million ($22.23 million) public offering | precision medicine | phase 2 in osteoarthritis
• Cognition Therapeutics (United States): $11.5 million public offering | CNS therapies | phase 2 in mild to moderate Alzheimer’s disease
• Nkarta (United States): $240 million public offering | CAR NK cell therapies | phase 1 in lupus nephritis

April 2024: 

• Praxis Precision Medicines (United States): $200 million public offering | central nervous system therapies | phase 3 in essential tremor
• Boundless Bio (United States): $100 million initial public offering | precision oncology | phase 1 in oncogene-related cancers
• Stoke Therapeutics (United States): $125 million public offering | RNA-based medicines | phase 1/2 in Dravet syndrome
• Contineum Therapeutics (United States) : $110 million IPO | small molecules | phase 1 in idiopathic pulmonary fibrosis and multiple sclerosis
• Longeveron (United States) : $5.25 million public offering | cell therapies | phase 2 in hypoplastic left heart syndrome
• Nurix Therapeutics (United States) : $175 million public offering | small molecules and antibody therapies | phase 1 in B-cell cancers
• TScan Therapeutics (United States) : $150 million public offering | T cell receptor therapies | phase 1 in blood cancers
• Biohaven (United States) : $230 million public offering | neuroscience and cancer drugs | phase 3 in obsessive compulsive disorder
• Longeveron (United States) : $11.4 million public offering | cell therapies | phase 2 in hypoplastic left heart syndrome

January 2024: 

• Fortress Biotech (United States): $11 million Post-IPO equity | drug development | phase 3 in metastatic cancer
• Vaxart (United States): $10 million Post-IPO equity | vaccine pills | phase 2 in Norovirus and COVID-19
• Effector Therapeutics (United States): $15 million Post-IPO equity | selective translation regulator inhibitors | phase 2b in non-small cell lung cancer
• Checkpoint Therapeutics (United States): $14 million Post-IPO equity | cancer therapies | awaiting approval for metastatic cutaneous squamous cell carcinoma drug
• Voyager Therapeutics (United States): $100 million Post-IPO equity | neurogenetic medicine | IND-enabling studies in Alzheimer’s disease
• Aptose (United States): $8.4 million Post-IPO equity | precision oncology | phase 1 in acute myeloid leukemia

February 2024: 

• NexImmune (United States): $3.67 million Post-IPO equity | T cell-mediated therapies | phase 1/2 in acute myeloid leukemia
• Jasper Therapeutics (United States): $50 million Post-IPO equity | antibody therapies | clinical in chronic spontaneous urticaria
• CRISPR Therapeutics (Switzerland): $280 million Post-IPO equity | CRISPR/Cas9 technology | clinical in CD19+ malignancies and autoimmune diseases
• Sensorion (France): €50.5 million ($54.04 million) Post-IPO equity | hearing loss restoration | phase in sudden sensorineural hearing loss
• Clearside Biomedical (United States): $15 million Post-IPO equity | eyecare and drug delivery | phase 3 in uveitic macular edema

March 2024:

• BioXcel Therapeutics (United States): $25 million Post-IPO equity | neuroscience and immuno-oncology | phase 3 in Alzheimer’s disease
• Sangamo Therapeutics (United States): $24 million Post-IPO equity | genomic medicine | preclinical in chronic neuropathic pain

April 2024:

• Vaccinex (United States): $1.5 million Post-IPO equity and PIPE | monoclonal antibodies | phase 2 in Alzheimer’s disease
• Oculis (Switzerland) : $59 million Post-IPO equity | eye care | phase 3 in diabetic macular edema
• Bio-Path Holdings (United States) : $1.2 million Post-IPO equity | RNA nanoparticle technology | phase 2 in blood cancers

January 2024: 

• BridgeBio Pharma (United States): up to $1.25 billion in Post-IPO Debt | genetic disease therapies | phase 3 in transthyretin amyloidosis

April 2024:

• Sensorion (France) : €15 million ($16.29 million) reserved offering | hearing disorder therapies | phase 2 in sudden sensorineural hearing loss

January 2024: 

• Remix Therapeutics (United States): $60 million | RNA therapeutics | phase 1 in adenoid cystic carcinoma
• C4 Therapeutics (United States): $25 million | targeted protein degradation | clinical in multiple myeloma & non-Hodgkin’s lymphoma
• DelSiTech (Finland): €10 million ($10.88 million) | drug delivery | clinical in chronic hepatitis B
• Locus Biosciences (United States): $23.9 million  | precision medicine | phase 2 in urinary tract infections
• Eyconis (United States): launches with $150 million Series unknown | eyecare therapies

March 2024:

• Mission Therapeutics (United Kingdom): £25.2 million ($​​32 million) | deubiquitylating enzyme inhibitors | phase 2 in cardiac surgery-associated kidney injury
• Profluent (United States): $35 million financing | AI-enabled protein design

April 2024:

• Sutro Biopharma (United States): $75 million | antibody drug conjugates | phase 2/3 in ovarian cancer
• EnteroBiotix (United Kingdom) : £27 million ($34.27 million) financing | microbiome medicines | phase 2 in irritable bowel syndrome
• Metsera (United States) : $290 million | obesity and metabolic disease medicines | phase 1 in obesity
• Theolytics (United Kingdom) : £19 million ($24.5 million) financing | preclinical in ovarian cancer